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Abstract 
Minimal change nephrotic syndrome (MCNS) is a common form of nephrotic 
syndrome (NS). We herein present the case of a 57-year-old woman with advanced 
lung adenocarcinoma treated with the tyrosine kinase inhibitor (TKI) gefitinib who 
developed NS. A renal biopsy revealed minor glomerular abnormalities, and the 
patient’s symptoms improved exclusively with the discontinuation of gefitinib. 
Therefore, we diagnosed her with MCNS associated with gefitinib treatment. A few 
months later, however, she developed recurrent lung tumors. Following the 
challenging initiation of the TKI erlotinib, she achieved remission without proteinuria. 
We thus conclude that erlotinib is a potential treatment option in patients with NS 
associated with gefitinib therapy. 
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Introduction 
Minimal change nephrotic syndrome (MCNS) is a common form of nephrotic 
syndrome (NS). Most cases of MCNS are idiopathic, although various drugs, 
neoplasms, infections and atopic attacks have been reported to be associated with its 
onset (1). Numerous agents may cause drug-induced NS, primarily including 
non-steroid anti-inflammatory drugs (NSAIDs) and antimicrobials (1). In contrast, 
gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, rarely 
causes drug-induced NS, with only one case having been previously reported (2). 
We herein present the case of a 57-year-old woman with advanced lung 
adenocarcinoma treated with gefitinib who developed NS. A renal biopsy revealed 
minor glomerular abnormalities, and the patient’s symptoms improved exclusively with 
the discontinuation of gefitinib. A few months later, however, computed tomography 
(CT) revealed new pulmonary nodules, which were thought to be derived from the 
recurrence of cancer. The patient subsequently received erlotinib as the next-line 
therapy and achieved remission, without proteinuria. In this report, we present the 
clinical course of our patient, the details of which suggest the usefulness of alternative 




The patient was a 57-year-old woman with no history of smoking. She had received a 
diagnosis of a right lung adenocarcinoma at 48 years of age and consequently 
underwent lobectomy of the right lower lung with mediastinal lymph node resection. 
The pathological stage was pT1N0M0; therefore, no additional treatment was 
required. As no recurrence was detected five years after the surgery, follow-up was 
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discontinued. 
A chest X-ray obtained at 56 years of age revealed no abnormalities; 
however, the patient experienced dyspnea six months later, which did not improve. 
She therefore visited our hospital, and a chest X-ray showed right pleural effusion. 
Further examinations, including cytological assessments of the pleural effusion and 
CT scanning, revealed a lung adenocarcinoma with an EGFR exon 19 deletion, with a 
pathological stage of T4N0M1a. The tumor was considered to be inoperable, and the 
patient was prescribed the tyrosine kinase inhibitor gefitinib (250 mg/day). The pleural 
effusion disappeared immediately after treatment, and gefitinib was assumed to have 
been effective at that time. 
Six months later, the patient suddenly developed edema of the lower limbs in 
addition to weight gain and again visited our hospital. The laboratory data showed 
hypoalbuminemia, hyperlipidemia and heavy proteinuria, findings strongly suggestive 
of NS. Although gefitinib had achieved a pathologically complete response to the lung 
adenocarcinoma, the drug was strongly suspected to be the cause of the NS. The 
dose of gefitinib was therefore discontinued, and the patient was admitted to our 
hospital for a further examination. 
On admission, the patient was found to have a blood pressure of 106/43 
mmHg and pulse of 61 beats/min with a regular rhythm. Edema of the lower limbs was 
evident; however, the neurological findings were unremarkable. Meanwhile, a chest 
X-ray demonstrated clear lung fields (Fig. 1), the findings of electrocardiography were 
normal and the results of 18-fluoro-2-deoxyglucose positron emission tomography 
(FDG-PET) were negative. The laboratory data were as follows: blood urea nitrogen 
(BUN), 13.3 mg/dL; serum creatinine, 0.61 mg/dL; serum total protein (TP), 4.5 g/dL; 
serum albumin (Alb), 1.8 g/dL; serum total cholesterol, 297 mg/dL; and 
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carcinoembryonic antigen (CEA), 4.8 ng/mL. The 24-hour urine protein excretion was 
8.3 g/day, and the selectivity index was 0.17. Based on these findings, we made a 
diagnosis of NS and subsequently performed a renal biopsy. Of the 34 glomeruli 
examined via light microscopy, two were globally sclerosed. The remaining 32 
glomeruli exhibited a slight increase in the mesangial matrix, although no increases in 
the number of mesangial cells were observed (Fig. 2a). Partially mild tubular atrophy 
and fibrosis were noted in the interstitium. Immunofluorescence microscopy did not 
reveal any glomerular deposits of complement or immunoglobulins, whereas electron 
microscopy showed minor glomerular abnormalities with partial foot process 
effacement (Fig. 2b). Therefore, we diagnosed the patient with MCNS. 
Following the discontinuation of gefitinib, the patient’s proteinuria gradually 
decreased, without the administration of corticosteroids. Two months later, the TP and 
Alb levels were 6.7 g/dL and 4.0 g/dL, respectively, and the degree of proteinuria was 
within the normal range, indicating complete remission. Finally, we confirmed the 
diagnosis of MCNS associated with gefitinib treatment. A few months after the 
discontinuation of gefitinib, however, CT revealed two new nodular lesions near the 
right pleura, which suggested the recurrence of cancer (Fig. 3). Following a detailed 
explanation of the potential adverse effects, the patient provided her informed consent 
for treatment with another tyrosine kinase inhibitor, erlotinib (100 mg/day). Fortunately, 
a follow-up CT scan obtained two months after the initiation of erlotinib revealed the 
disappearance of the nodular lesions. The patient subsequently achieved a 
pathological complete response with respect to the lung cancer, without proteinuria, 
i.e., there was no evidence of recurrence of NS (Fig. 4). 
 
Discussion 
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We herein reported the case of a patient with MCNS associated with gefitinib 
treatment in which the administration of erlotinib was successful in treating recurrent 
lung cancer without causing proteinuria. Most cases of MCNS are idiopathic, although 
various drugs, neoplasms, infections and atopic attacks have been reported to be 
associated with its onset (1). Therefore, it is important to obtain an accurate 
differential diagnosis for selecting subsequent treatment. Regarding the differential 
diagnosis in this case, we first excluded the possibility of infection or atopic attacks, as 
the patient exhibited neither signs or symptoms nor other findings suggestive of these 
diseases. We next considered the potential for other neoplasms, since hematologic 
malignancies, such as Hodgkin lymphoma, non-Hodgkin lymphoma and leukemia, 
may be associated with MCNS (3). Although there are a few case reports suggesting 
a relationship between MCNS and lung cancer (4-6), the present patient’s laboratory 
data and CT and FDG-PET findings did not reveal any malignancies, except for the 
lung adenocarcinoma noted at the onset of NS. While we cannot completely exclude 
the possibility of idiopathic MCNS, our patient achieved complete remission two 
months after the discontinuation of gefitinib, which is a much shorter time period than 
that usually observed for spontaneous remission in cases of idiopathic MCNS (7). 
Additionally, based on the fact that the NS improved exclusively following the 
discontinuation of gefitinib and the patient did not develop NS after receiving erlotinib 
as the next-line therapy for the recurrent lung cancer, we diagnosed her condition as 
MCNS associated with the administration of gefitinib. 
Gefitinib is an EGFR tyrosine kinase inhibitor (8) that is reportedly effective 
in patients with tumors containing EGFR mutations (9, 10). The most common 
adverse effects of gefitinib treatment are rashes, diarrhea, acne, dry skin, nausea and 
vomiting. Although gefitinib-related interstitial lung disease is a well-known serious 
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side effect that may result in death (11), most adverse effects of this drug are 
mild-to-moderate in nature and do not require the discontinuation of therapy (12). To 
date, adverse renal effects have been reported in only a few cases (2, 13, 14). 
Kumasaka et al. (2) first reported a case of MCNS associated with gefitinib treatment. 
In that case, NS developed four months after the initiation of gefitinib therapy, 
suggesting that the occurrence of NS associated with gefitinib is a late-onset adverse 
effect, as noted in our case. Furthermore, Wan et al. (13) reported a case of acute 
kidney injury associated with gefitinib therapy. In both of these prior cases, as seen in 
our patient, only the discontinuation of treatment improved the NS and renal 
dysfunction. 
Erlotinib is another widely used EGFR tyrosine kinase inhibitor. One 
retrospective study found no significant differences between erlotinib and gefitinib in 
terms of progression-free survival, although more adverse events were reported in the 
erlotinib-treated group, including rashes, anorexia and constipation (15). Adverse 
renal events are extremely rare in patients undergoing erlotinib treatment, including 
only one case report of double antineutrophil cytoplasmic autoantibody 
(ANCA)-negative pauci-immune crescentic glomerulonephritis (16). In contrast, no 
cases of NS associated with erlotinib have been reported to date. On the other hand, 
interestingly, animal experiments have shown that erlotinib reportedly attenuates 
proteinuria and inhibits the development of diabetic nephropathy (17). Therefore, the 
effects of erlotinib treatment on the kidneys are currently under investigation. 
The present case raises the important question as to why erlotinib does not 
cause NS, although its mechanism of action is similar to that of gefitinib, in terms of its 
function as an EGFR tyrosine kinase inhibitor. One possible explanation for this 
phenomenon is that the cause of drug-induced NS is related to drug hypersensitivity 
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reactions. Mihovilovic et al. (18) reported a patient with repeated episodes of NS 
induced by NSAIDs, including diclofenac and meloxicam, in which the administration 
of celecoxib, a cyclooxygenase (COX)-2 selective NSAID, interestingly did not induce 
the onset of NS, suggesting that a difference in chemical structure between these 
drugs may play a role in hypersensitivity reactions. Similarly, the difference in the 
chemical structures of gefitinib and erlotinib may explain the differences in the 
reactions in the kidneys to these two drugs. The effects of the long-term use of 
erlotinib on the kidneys remain unknown; therefore, further careful monitoring is 
required in the current case. 
In conclusion, clinicians should consider the possibility of MCNS associated 
with gefitinib treatment in NS patients receiving gefitinib therapy. Erlotinib is a potential 
treatment option in patients with MCNS associated with the administration of gefitinib. 
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Chest X-ray obtained on admission showing no abnormalities. 
 
Figure 2 
Renal biopsy findings. (a) A slight increase in the mesangial matrix was observed 
without an increase in the number of mesangial cells (periodic acid-Schiff staining, 




Computed tomography performed after the discontinuation of gefitinib showing two 
new nodular lesions near the right pleura (arrows).  
 
Figure 4 
Clinical course. U-pro: urinary protein, g/gCr: urinary protein/creatinine ratio 
 




